In a phase II cluster RCT of 61 patients with renal cell or thyroid cancer starting VEGFR tyrosine kinase inhibitors, intensive SBP control (<120 mm Hg) vs usual care (<140) lowered SBP by 12.2 mm Hg at 1 month and 7.6 at 3 months; difference at 6 months not significant.
RCTn = 61
Ky et al. Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191